# OnCo record lux-lung-3 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/lux-lung-3/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "lux-lung-3", "NCT00949650" ;
  schema:name "LUX-Lung 3"@en ;
  schema:description "Showed that the second-generation EGFR pill afatinib beats chemotherapy for lung cancers driven by an EGFR mutation, and that the benefit is largest for the two common mutations."@en ;
  schema:url <https://onco.cc/trials/lux-lung-3/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00949650>, <https://doi.org/10.1200/JCO.2012.44.2806> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/lung-adenocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:companies <https://onco.cc/companies/boehringer-ingelheim/> ;
  onco:terms <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/terms/egfr-mutation-subtypes/>, <https://onco.cc/terms/tki-term/> ;
  onco:trials <https://onco.cc/trials/flaura/> .